Maemoto Ryo, Tsujinaka Shingo, Miyakura Yasuyuki, Machida Erika, Fukui Taro, Kakizawa Nao, Tamaki Sawako, Ishikawa Hideki, Rikiyama Toshiki
Surgery, Saitama Medical Center, Jichi Medical University, Saitama, JPN.
Cureus. 2021 May 12;13(5):e14983. doi: 10.7759/cureus.14983.
Introduction Surgery for patients taking antithrombotic drugs for the prevention and treatment of cardiovascular disease, including anticoagulants and antiplatelet drugs, is increasing because of the aging society. In patients with moderate to high risk for cardiovascular events, receiving antiplatelet therapy, and requiring noncardiac surgery continuing antiplatelet drugs perioperatively is recommended. To date, there have been limited reports on the risk of secondary bleeding after proctological surgery in patients who are administered antithrombotic drugs. The purpose of this study was to identify the incidence and severity of secondary bleeding after proctological surgery for patients with or without antithrombotic therapy. Methods We retrospectively identified 113 patients who underwent proctological surgery in our hospital from March 2009 to February 2019. In general, antiplatelet drugs were continued and anticoagulant drugs were either substituted or withdrawn prior to surgery. The severity of secondary bleeding was classified as mild, moderate, or severe. Results Eighteen patients underwent antithrombotic therapy (A group) and 95 patients did not undergo antithrombotic therapy (N group). Secondary bleeding was observed in nine patients (8.0%) and patients in the A group exhibited a significantly higher rate of secondary bleeding than those in the N group (39% vs. 2.4%, P < 0.01). The median interval from surgery to the onset of secondary bleeding was five days (range: 0-11). The severity of bleeding was the highest in patients administered direct oral anticoagulants (DOAC) and was the lowest in those administered aspirin. There was no mortality or cardiovascular event. Conclusion Antithrombotic therapy carries a high risk of secondary bleeding after proctological surgery. Delaying the postoperative resumption of anticoagulants is considered while balancing the risk of postoperative thromboembolic complications against secondary bleeding.
引言 由于社会老龄化,为预防和治疗心血管疾病而服用抗血栓药物(包括抗凝剂和抗血小板药物)的患者接受手术的情况日益增多。对于有中度至高度心血管事件风险、正在接受抗血小板治疗且需要进行非心脏手术的患者,建议围手术期继续使用抗血小板药物。迄今为止,关于接受抗血栓药物治疗的患者在直肠外科手术后发生继发性出血风险的报道有限。本研究的目的是确定接受或未接受抗血栓治疗的患者在直肠外科手术后继发性出血的发生率和严重程度。
方法 我们回顾性分析了2009年3月至2019年2月在我院接受直肠外科手术的113例患者。一般来说,抗血小板药物在手术前继续使用,抗凝药物则在手术前替换或停用。继发性出血的严重程度分为轻度、中度或重度。
结果 18例患者接受了抗血栓治疗(A组),95例患者未接受抗血栓治疗(N组)。9例患者(8.0%)出现继发性出血,A组患者继发性出血发生率明显高于N组(39%对2.4%,P<0.01)。从手术到继发性出血发作的中位间隔时间为5天(范围:0-11天)。接受直接口服抗凝剂(DOAC)治疗的患者出血严重程度最高,接受阿司匹林治疗的患者出血严重程度最低。没有死亡病例或心血管事件发生。
结论 抗血栓治疗在直肠外科手术后有较高的继发性出血风险。在平衡术后血栓栓塞并发症风险与继发性出血风险的同时,考虑延迟术后抗凝剂的恢复使用。